United Bank Acquires 11,015 Shares of Medtronic PLC $MDT

United Bank raised its stake in shares of Medtronic PLC (NYSE:MDT) by 132.1% during the first quarter, Holdings Channel reports. The firm owned 19,352 shares of the medical technology company’s stock after buying an additional 11,015 shares during the period. United Bank’s holdings in Medtronic were worth $1,677,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. ARQ Wealth Advisors LLC raised its holdings in shares of Medtronic by 478.2% in the 1st quarter. ARQ Wealth Advisors LLC now owns 26,983 shares of the medical technology company’s stock worth $2,338,000 after buying an additional 22,316 shares in the last quarter. Diversify Wealth Management LLC boosted its stake in Medtronic by 51.6% in the 1st quarter. Diversify Wealth Management LLC now owns 98,447 shares of the medical technology company’s stock valued at $7,814,000 after buying an additional 33,500 shares in the last quarter. Valmark Advisers Inc. boosted its stake in Medtronic by 20.5% in the 1st quarter. Valmark Advisers Inc. now owns 5,663 shares of the medical technology company’s stock valued at $491,000 after buying an additional 965 shares in the last quarter. Carnegie Investment Counsel grew its position in Medtronic by 64.3% in the first quarter. Carnegie Investment Counsel now owns 6,421 shares of the medical technology company’s stock valued at $556,000 after acquiring an additional 2,513 shares during the period. Finally, 180 Wealth Advisors LLC grew its position in Medtronic by 3.1% in the first quarter. 180 Wealth Advisors LLC now owns 39,773 shares of the medical technology company’s stock valued at $3,446,000 after acquiring an additional 1,211 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on MDT shares. Sanford C. Bernstein cut their price objective on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Wells Fargo & Company lowered their target price on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Rothschild & Co Redburn dropped their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. UBS Group cut their price target on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Finally, Citigroup reduced their price target on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $98.17.

Medtronic Price Performance

Shares of NYSE:MDT traded up $1.39 during midday trading on Friday, reaching $83.78. The company’s stock had a trading volume of 7,190,992 shares, compared to its average volume of 8,643,010. The business’s fifty day simple moving average is $79.11 and its 200-day simple moving average is $88.53. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a market capitalization of $107.24 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.25 and a beta of 0.56.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen cut its price target on Medtronic to $100 from $119 but kept a buy rating, signaling the stock still has meaningful upside from current levels. TD Cowen lowers price target on Medtronic
• Positive Sentiment: Another recent bullish note said Medtronic’s guidance is conservative and “built to be beaten,” highlighting strong fiscal 2026 revenue growth and potential upside catalysts from the MiniMed separation, tariff refunds, and payment relief. Medtronic guidance built to be beaten
• Positive Sentiment: Another Seeking Alpha article argued Medtronic is undervalued and that tailwinds are just beginning, reinforcing the idea that investors may be underappreciating the company’s growth potential. Medtronic undervalued and tailwinds just getting started
• Positive Sentiment: Citi also reportedly initiated or reiterated a buy view on Medtronic, adding to the wave of favorable analyst sentiment. Medtronic receives a buy from Citi
• Neutral Sentiment: Medtronic disclosed a voluntary global recall of its Octopus 4 Tissue Stabilizer after an assembly issue affecting 590 units. The issue appears limited, but recalls can create short-term investor caution. Medtronic recalls Octopus 4 Tissue Stabilizer
• Neutral Sentiment: Separate valuation pieces on Medtronic suggest the stock remains cheap relative to fundamentals, but these are more interpretation than hard catalysts for the share price. Medtronic stock could be undervalued

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).